Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.

類似資料

• Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. Newcastle and Northern Lymphoma Group.
  著者:: Jackson, G. H., 等
  出版事項: (1994)
• Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.
  著者:: Seymour, L. K., 等
  出版事項: (1994)
• High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.
  著者:: Zulian, G. B., 等
  出版事項: (1989)
• Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database
  著者:: Desai, Ami V., 等
  出版事項: (2016)
• Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation
  著者:: Frankiewicz, Andrzej, 等
  出版事項: (2018)